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sphingosine, which is known to inhibit
store-operated calcium release cal-
cium current (iCRAC). More definitive
evidence is needed for the link be-
tween phospholipase D and SphK1
(or SphK2). The mechanism by which
extracellular S1P enhances mast cell
responsiveness is not addressed by
Olivera et al. (2007), but extrapolation
of the data from studies of S1P recep-
tor-deficient BMMC (Jolly et al., 2004)
strongly suggest that it is through
S1P2. Finally, the findings of Olivera
et al. (2007) suggest that S1P derived
from SphK1 and SphK2 are segre-
gated in separate pools or compart-
ments, one of which is exported via
ABCC1 (SphK1 pool) and the other
(SphK2 pool) acts internally tomobilize
calcium for cell activation. If so, this
raises challenging questions for future
research as to how S1P, with its highly
lipophilic chain, is segregated, trans-
ported within and outside the cell, and
appropriately presented to its targets.
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Tim molecules regulate T cell responses; however, the molecular basis of their ligand recognition re-
mains largely unknown. In this issue of Immunity, Santiago et al. (2007) andCao et al. (2007) report the
crystal structures of several Tims and provide insights into the structure-function relationship of
these molecules.The recently discovered Tim (T cell
immunoglobulin mucin domain; also
known as TIM) family has emerged as
an important player in regulating T
cell responses. The Tim family con-
sists of eight members in mice (Havcr1
[Tim-1], Timd2 [Tim-2], Havcr2 [Tim-3],
Timd4 [Tim-4], three genes that are
predicted to encode Tims 5–7, and
Dppa 1 [Tim-8]; the proteins are also
referred to as mTIM-1, etc.) and three
members in humans (HAVCR1 [TIM-1],
HAVCR2 [TIM-3], and TIMD4 [TIM-4]).
In mice, the genes encoding Tim pro-
teins are encoded on mouse chromo-
some 11 in a genetic interval that has
shown linkage to a number of autoim-
mune diseases, allergy, and atopy aswell as asthma (Kuchroo et al., 2003).
The syntenic region in humans, 5q33,
has also been associated with asthma
(McIntire et al., 2001). Furthermore,
comparisons of the genes encoding
Tim proteins in different strains of mice
have revealed polymorphisms in those
encoding Tim-1 and Tim-3, but not
Tim-2 and Tim-4. Interestingly, Th1-
prone strains (i.e., C57BL/6) and Th2-
prone strains (i.e., Balb/c) express
different Havcr1 (Tim-1) and Havcr2
(Tim-3) polymorphisms (Meyers et al.,
2005). Indeed, mounting data support
that the Tims are important regulators
of effector T cells. Both mouse and hu-
man studies suggest a role for Tim-3 in
regulating Th1 immunity and toleranceImmunity(Anderson and Anderson, 2006). Tim-1
has been shown to act as a costimula-
tory molecule and may have a special-
ized role in regulating Th2 responses
(Meyers et al., 2005). Similarly, Tim-2
appears to be an important negative
regulator of Th2 responses (Chakra-
varti et al., 2005). Tim-4 is exclusively
expressed on antigen-presenting cells
in the mouse and is a natural ligand for
Tim-1 (Meyers et al., 2005). Thus, cur-
rent data point to the Tim genes as im-
portant regulators of both Th1 and Th2
immunity and possibly as important
determinants for susceptibility to both
autoimmune and allergic diseases.
All of the Tim molecules share a
common structural organization26, March 2007 ª2007 Elsevier Inc. 273
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Previewsconsisting of an N-terminal IgV domain
followed by a mucin domain, a trans-
membrane domain, and a cytoplasmic
tail. Of note are the four noncanonical
cysteines in the IgV domain that are
conserved in all the Tims in both
mouse and man. In this issue of Immu-
nity, Santiago et al. (2007) and Cao
et al. (2007) report the crystal struc-
tures of mouse Tim-1, Tim-2, and
Tim-3 and show that these four cyste-
ines result in the formation of two di-
sulfide bonds that reposition the clas-
sical loops formed between the F and
G and C and C0 strands of the b sheet
(FG and CC0 loops) to form a unique
binding cleft (FG-CC0 cleft) not seen
in the Ig domain of any other Ig super-
family members (Cao et al., 2007; San-
tiago et al., 2007).
Thus far, galectin-9 has been identi-
fied as a ligand for Tim-3 (Zhu et al.,
2005), both Semaphorin 4a (Sema4a)
and H-ferritin for Tim-2, and both
hepatitis A virus (HAV) and Tim-4 for
Tim-1 (Chen et al., 2005; Kuchroo
et al., 2003; Meyers et al., 2005). Inter-
estingly, Santiago et al. (2007) andCao
et al. (2007) demonstrate that the
unique FG-CC0 cleft is responsible
neither for galectin-9 binding to Tim-3
nor HAV or Tim-4 binding to Tim-1
(Figure 1; Cao et al., 2007; Santiago
et al., 2007). Thus, the presence of
the FG-CC0 cleft opens the door for
the possibility of as-yet-undiscovered
Tim ligands. Indeed, Cao et al. (2007)
show that unglycosylated Tim-3 IgV,
which cannot bind to galectin-9, binds
to several primary cell types and trans-
formed cell lines from different spe-
cies. Mutations in residues affecting
the FG-CC0 cleft abolish this binding.
Collectively, these findings support
the existence of one ormore evolution-
arily conserved Tim-3 ligands that oc-
cupy the unique FG-CC0 cleft (Cao
et al., 2007).
That the FG-CC0 cleft is a common
feature of all the Tims does not neces-
sitate that they all recognize a common
ligand. In fact, Santiago et al. (2007)
show that the CC0 loop in Tim-2 has
a markedly different conformation
than that in Tim-1, which is more rep-
resentative of the conformation seen
in the rest of the Tims. This different
conformation of the CC0 loop in Tim-2
likely mediates binding to different274 Immunity 26, March 2007 ª2007 ElsFigure 1. Schematic Representation of the Mouse Tim Family Proteins and Their
Ligands
Tim-4 can bind to Tim-1 to costimulate T cell activation and expansion. Tim-1 can also form ho-
mophilic interaction. Tim-2 proteins form a dimer that prevents homophilic binding. Semaphorin
4A (Sema4A) and H-ferritin have been identified as Tim-2 ligands. Galectin-9 binds to Tim-3 via
carbohydrates present on the IgV domain. An unknown ligand(s) that is widely expressed in
many cell types can interact with Tim-3 independent of Tim-3 glycosylation by involving the
FG-CC0 cleft on the opposite side of the Tim-3 IgV domain. The cleft in Tim-3 is a feature shared
by all Tim proteins. Glycosylation affects not only Tim protein structures but also their interaction
with their ligands. The existence of multiple ligands for Tim proteins and the possibility of their own
association suggest that each Tim protein might deliver multiple differential signals in regulating
T cell responses such as activation, proliferation, differentiation, and death, depending on the
receptor-ligand interaction.ligands via the FG-CC0 cleft and may
in part explain the different functions
of these two molecules in that Tim-1
appears to be costimulatory whereas
Tim-2 is inhibitory. Furthermore, the
structures of Tim-1 and Tim-2 reported
by Santiago et al. (2007) demonstrate
that Tim-2 forms a dimer and that ho-
mophilic Tim-1:Tim-1 interactions can
take place on neighboring cells (Fig-
ure 1). The fact that this homophilic
Tim-1 interaction is conserved in hu-
man TIM-1 suggests that it is biologi-
cally important. Lastly, Santiago et al.
(2007) show that the carboyhydrate
residues in the Tim-1 mucin domain
also influence Tim-1 binding. Thus, al-
though the Tims have common overall
binding features such as the FG-CC0
cleft, unique sequence differences in
the IgV and mucin domains will resultevier Inc.in differential ligand binding (Santiago
et al., 2007).
All of these structural data have nu-
merous implications for the biochemi-
cal signaling pathways triggered by the
Tims. Indeed, Santiago et al. (2007)
observe that homophilic Tim-1 binding
is responsible for Tim-1 clustering at
the intercellular junction of transfected
cells. This clustering could presumably
facilitate aggregation and phosphory-
lation of signaling mediators. Indeed,
this could underlie the observed phos-
phorylation of Tim-1 and activation of
NFAT and AP-1 in T cells and T cell
lines overexpressing Tim-1 (de Souza
et al., 2005; Santiago et al., 2007).
Similarly, the dimerization of Tim-2
may facilitate aggregation of signaling
mediators and may provide an expla-
nation for the ligand-independent
Immunity
Previewsrepression of NFAT and AP-1 that has
been reported in Tim-2 transfectants
(Knickelbein et al., 2006). The exis-
tence of multiple binding modes could
translate into triggering of multiple
biochemical signaling modes and
different functional outcomes depend-
ing on which ligand(s) are binding to
the Tims. Lastly, whether signaling
pathways will synergize or antagonize
if two ligands bind to two different
faces of the Tim molecules remains
to be seen.
Thus, the accumulating biological
data that underscore the importance
of the Tim molecules in immunity
together with the structural data dis-
cussed above highlight the need for
understanding the complex interaction
of Tim molecules with their ligands.
How can this all take place? One can
envision that the regulation of complex
ligand:receptor interactions could take
place at different levels such as the an-
atomic distribution of different ligands,Aiolos: An Ungra
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Ikaros family members play an im
show that pre-BCR signaling indu
the pre-BCR component l5 and e
Ikaros burst into the scene of immune
gene regulation in the early nineties
(Georgopoulos et al., 1992; Lo et al.,
1991), leading to a flurry of research
that has generated a lot of data, not
always concordant. This seems likely
to be due to the multifarious potential
activities of this factor. Ikzf1, the gene
encoding Ikaros, is the prototype
member of a family of five known
(so far) genes, three of which have a
hematopoietic pattern of expression.differential affinity for different ligands,
and the modulation of the expression
of the Tims and different Tim ligands
by environmental triggers such as in-
flammation. The identification of novel
Tim ligands, their expression pattern
and measurements of the affinity of
different Tim:ligand pairs, and the elu-
cidation of the pattern and regulation
of Tim and Tim ligand expression will
likely fuel investigation in this field for
many years to come.
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is localized at pericentric heterochro-
matin, suggesting that genes bound
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tive compartments of the nucleus
(Brown et al., 1997; Hahm et al., 1998).
In this issue of Immunity, Thompson
et al. (2007) add another new and inter-
esting facet on the profile of this family
of factors. In early B cell development,
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the gene encoding l5, a component
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